Gene therapy for Duchenne muscular dystrophy

Naoki Suzuki, Yuko Miyagoe-Suzuki, Shin'ichi Takeda

Research output: Contribution to journalReview article

Abstract

Gene therapy has great potential to treat Duchenne muscular dystrophy. Among many proposed strategies to deliver a therapeutic gene to muscle, recombinant adeno-associated virus-mediated gene transfer is the most promising. The recent isolation of new adeno-associated virus serotypes from human and nonhuman primates provides the opportunity to develop vectors that can achieve the long-term expression of a therapeutic gene in muscles of the entire body without detrimental effects. To translate the results from small animal models to clinical trials in humans, further work using larger animal models, such as dystrophic dogs or nonhuman primates, is required. This review also discusses recent progress in other gene transfer-related therapeutic approaches, including targeted exon skipping and gene correction.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalFuture Neurology
Volume2
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1
Externally publishedYes

Keywords

  • Adeno-associated virus vector
  • Duchenne muscular dystrophy
  • Dystrophin
  • Exon skipping
  • Gene therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Gene therapy for Duchenne muscular dystrophy'. Together they form a unique fingerprint.

  • Cite this

    Suzuki, N., Miyagoe-Suzuki, Y., & Takeda, S. (2007). Gene therapy for Duchenne muscular dystrophy. Future Neurology, 2(1), 87-96. https://doi.org/10.2217/14796708.2.1.87